GeoVax Labs Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,513.90
1,101.70
1,060.30
454.00
312.70
259.70
Total Accounts Receivable
140.90
79.30
120.00
28.10
59.80
121.80
Other Current Assets
43.60
44.50
56.60
62.30
75.60
238.20
Total Current Assets
2,698.30
1,225.50
1,237.00
544.40
448.10
619.70
Net Property, Plant & Equipment
120.20
96.70
83.60
54.80
31.20
11.40
Intangible Assets
10.00
-
-
-
-
-
Other Assets
11.00
11.00
11.00
11.00
11.00
11
Total Assets
2,839.60
1,333.20
1,331.60
610.20
490.20
642.10
Accounts Payable
155.90
55.60
100.90
75.60
77.60
Other Current Liabilities
156.40
131.40
26.10
294.20
733.70
Total Current Liabilities
312.30
187.00
127.00
369.80
811.30
Total Liabilities
312.30
187.00
127.00
369.80
811.30
Common Equity (Total)
1,211.10
1,070.10
144.60
776.40
2,220.10
Total Shareholders' Equity
2,527.20
1,146.20
1,204.60
240.40
321.10
Total Equity
2,527.20
1,146.20
1,204.60
240.40
321.10
Liabilities & Shareholders' Equity
2,839.60
1,333.20
1,331.60
610.20
490.20
Preferred Stock (Carrying Value)
1,316.20
76.10
1,060.00
1,016.80
1,899.10

About GeoVax Labs

View Profile
Address
1900 Lake Park Drive
Smyrna Georgia 30080
United States
Employees -
Website http://www.geovax.com
Updated 07/08/2019
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G.